Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 3/20 | 0.33 |
| ▸ | FPR2 | P25090 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | CDK9 | P50750 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 2/20 | 0.31 |
| ▸ | JAK1 | P23458 | 2/20 | 0.31 |
| ▸ | PIM1 | P11309 | 2/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | EP300 | Q09472 | 1/20 | 0.30 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5596666 | 0.82 | NOTUM (0.33) | NOTUM | |
| SCHEMBL5597009 | 0.80 | HTR2C (0.41) | HTR6HTR2AHTR2CHTR2B | |
| SCHEMBL5596331 | 0.79 | ROCK2 (0.38) | NOTUMHTR6CDK9PIM1DRD2 | |
| SCHEMBL5597035 | 0.77 | NOTUM (0.34) | NOTUMHTR6FPR2CDK9PIM1 | |
| SCHEMBL5596951 | 0.76 | HTR2C (0.50) | HTR2AHTR2CHTR2B | |
| SCHEMBL5596620 | 0.74 | DRD2 (0.39) | NOTUMHTR6CDK9JAK2JAK1 | |
| SCHEMBL5596996 | 0.74 | HTR6 (0.36) | NOTUMHTR6CDK9JAK2JAK1 | |
| SCHEMBL5596971 | 0.72 | HTR2C (0.48) | HTR2AHTR2CHTR2B | |
| SCHEMBL5597030 | 0.70 | PRKCZ (0.34) | HTR6PIM1DRD2PARP1 | |
| SCHEMBL15785123 | 0.69 | ALDH1A1 (0.54) | NOTUMHTR2AHTR2CHTR2BDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1829876-A1 | NITROGENEOUS TRICYCLIC COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2007-09-05 | — | — | EP | disclosed |
| US-20060247266-A1 | Nitrogen-containing tricyclic compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247266-A1 | Nitrogen-containing tricyclic compounds | MYO1B, CHRM1, MYL12A | NOTUM 4510/4885HTR6 1910/4885FPR2 3865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.